NJ’s leading dispensary increases product offerings after receiving state approval
BELLMAWR, N.J.–(BUSINESS WIRE)–Curaleaf New Jersey, a provider of state licensed cannabinoid-based products, today launched a new line of natural, terpene rich, strain specific, vaporable cannabis concentrates for patients of its Bellmawr dispensary. The first in New Jersey to manufacture products in this category, Curaleaf continues to set the industry standard by expanding its already-diverse medical cannabis product offerings. This new product line will help Curaleaf continue to provide quality care by offering a delivery form that addresses specific patient needs.
The newly-launched product is available initially in four varieties, Lavender, Strawberry Cough, Cookies and Canna-Tsu, all made with nothing but NJ Department of Health approved pharmaceutical-grade cannabis extract, strain specific cannabis and naturally derived terpenes. The product comes in the form of vaporizer cartridges and will soon be available in convenient disposable vape pens as well. Formulated by the Curaleaf team, these products are developed at the company’s cultivation and laboratory facility in Bellmawr using advanced extraction and processing techniques for the purest oil and most robust strain terpenes. The products are tested to ensure each cartridge has a standardized amount of THC and or CBD for a consistent patient experience.
“Receiving approval to launch these products is an important milestone in the progression of Curaleaf’s operations as well as in New Jersey’s medical cannabis program,” said George Schidlovsky, Curaleaf New Jersey’s president. “As the largest dispensary on the East Coast, serving hundreds of patients daily, Curaleaf has the resources and production capacity to reliably market and distribute new products that our patients depend on to live life well.”
“These concentrates, which surpass the state’s high standards of quality, provide an alternative method of administration for patients who may not be able to benefit from topical or oral forms of medical cannabis,” said Schidlovsky. “Vaporizing cannabis concentrate is considered a healthier alternative to smoking, and is a fast-acting form of administration. I look forward to seeing the positive effect it has on Curaleaf’s patients in New Jersey.”
Curaleaf complies with New Jersey state regulations and statutes that regulate e-vaping. While the company serves pediatric patients with a valid NJ Medical Marijuana card, it will not sell vaporizers to anyone under the age of 21.
Curaleaf is a leading vertically integrated cannabis operator in the United States. Headquartered in Wakefield, Massachusetts, Curaleaf has a presence in 12 states, owns and operates 28 dispensaries, 12 cultivation sites and nine processing sites with a focus on highly populated, limited license states, including Florida, Massachusetts, New Jersey and New York. Curaleaf leverages its extensive research and development capabilities to distribute cannabis products in multiple formats with the highest standard for safety, effectiveness, consistent quality and customer care. Curaleaf is committed to being the industry’s leading resource in education and advancement through research and advocacy. More information regarding Curaleaf can be found at www.curaleaf.com.
Samantha Qualls, 212-889-0808